Pfizer Stock News

Pfizer CEO Says Annual COVID Jabs Would Be An "Ideal Situation" Pfizer CEO Albert Bourla''s global media tour continued this week with a series of interviews with the Israeli press. Of course, Israel has become an extremely important market for Pfizer. After all, they buy massive quantities of their vaccines. A few weeks ago, Bourla was speaking with the French press, telling them he expected everything to "return to normal" by the Spring. France is of course another important customer for Pfizer''s vaccines. And with so much money at stake, it''s critical that a CEO must tend to propagate their preferred narrative with a carefully calculated global media strategy. In Israel, the first country in the world to start doling out a fourth COVID jab to those deemed most vulnerable to infection via omicron, Bourla told an Israeli TV station that he hopes people will ultimately only need boosters once a year, rather than every few months. Bourla said it would "not be a good scenario" if people were to get boosters every four to five months. "What I''m hoping [is] that we will have a vaccine that you will have to do once a year," he told Channel 12 news on Saturday.

The FDA has issued a Complete Response Letter (CRL) to Pfizer Inc (NYSE: PFE ) and OPKO Health Inc''s (NASDAQ: OPK ) somatrogon. Somatrogon is an investigational once-weekly long-acting recombinant human growth hormone for pediatric growth hormone deficiency (GHD). Pfizer is evaluating the FDA''s comments. Earlier this week, Japan''s Ministry of Health, Labour, and Welfare

Researchers Worry COVID Will Quickly Develop Resistance To New Pills From Pfizer And Merck If it wasn''t already bad enough that several experts have warned that US regulators are overlooking safety risks associated with the new generation of COVID therapeutic pills from Pfizer and Merck, researchers and regulators are also apparently worried that they might not even work - at least, not for long. According to a report in WSJ, researchers and academics are already taking steps to keep an eye out for signs that COVID is evolving in response to exposure to pills like Paxlovid and Molnupiravir. The hope is that the pills will save more lives, especially now that the vaccines and boosters have been surprisingly ineffective at prevent transmission and infection with the virus. "We know this is likely to happen at some point, so we need to beat it to the punch and nip it in the bud before it gets out of hand and starts to take over," said Katherine Seley-Radtke, a medicinal-chemistry professor at the University of Maryland, Baltimore County, whose lab is studying antiviral combination therapies.

Pfizer (PFE) CEO Albert Bourla thinks that an annual COVID-19 vaccine could be preferable over frequent booster shots in terms of public health.In an interview with Israel''s N12 News

Pfizer (PFE) and Merck (MRK), the developers of the first oral medications for COVID-19 in the U.S., are advancing combination studies for their antiviral therapies as experts flag the

New Hampshire Pharmacies Could Soon Begin Dispensing Ivermectin Without Doctor''s Prescription A bill working its way through the New Hampshire legislature would allow residents to receive ivermectin from pharmacies with a prescription of a doctor or an Advanced Practice Registered Nurse (APRN) for the off-label treatment of Covid-19. House Bill 2011 would allow pharmacists to "dispense ivermectin under the delegated prescriptive authority of the physician or APRN (Advanced Practice Registered Nurses) , specify a mechanism to document screening performed and the prescription in the patient''s medical record, and include a plan for evaluating and treating adverse events," reads the bill. "Any such prescription shall be regarded as being issued for a legitimate medical purpose in the usual course of professional practice." Ivermectin, a protease inhibitor (just like Pfizer''s new Covid pill), has come under attack ever since former President Trump suggested it as a potential treatment for Covid-19.

Pfizer, GE, Shopify, and Dana are among our panelists favorite investments for the year.

Pfizer Inc said on Friday the U.S. health regulator has declined to approve the treatment for growth hormone deficiency in children that it developed with partner OPKO Health Inc .

The FDA has issued Pfizer and OPKO Health a Complete Response Letter for their Biologics License Application for somatrogon.

The WHO has endorsed having children between the ages of 5 and 11 years old vaccinated with the Pfizer/BioNTech COVID-19 shot.

They found vaccine effectiveness was best after three doses of the Pfizer or Moderna vaccines in preventing Covid-19-associated emergency department and urgent care visits

NEW YORK , Jan. 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTON, AAPL, DIS, PFE, and NVDA. Full story available on Benzinga.com

''Much Brighter Than Before'': COVID-19 Cases Plunge Across US Authored by Zachary Stieber via The Epoch Times (emphasis ours), COVID-19 case counts have dropped across the United States in recent days, stoking optimism that the Omicron-fueled wave is subsiding. People stop outside a COVID-19 testing site in New York City on Jan. 10, 2022. (Scott Heins/Getty Images) Thirty-four states have recorded a decrease in cases in recent days, not including states that reported a single-day drop, according to an Epoch Times analysis. That includes some of the states that saw huge Omicron-fueled increases, including New York, California, and Florida. Omicron is one of the newest variants of Covid19. [ ZH ]: Other states that have seen fewer cases recently include Alabama, Delaware, Georgia, Louisiana, Nevada, North Dakota, Oregon, and Pennsylvania. States in every region of the country have reported fewer cases, and a smaller number have also seen a lower number of people being admitted to hospitals with or for COVID-19.

Stocks Analysis by Zacks Investment Research covering: Pfizer Inc, Macy’s Inc, ArcBest Corp. Read Zacks Investment Research''s latest article on Investing.com

The World Health Organization''s advisory panel on Friday recommended extending the use of a reduced dosage of Pfizer and German partner BioNTech''s COVID-19 vaccine to children aged 5 to 11 years old.